|
End-of-day quote
Dhaka S.E.
2026-10-06
|
5-day change | 1st Jan Change | ||
| 139.60 BDT | -2.24% |
|
-5.74% | +36.73% |
| 09-15 | Beximco Pharmaceuticals Confirms Reports of Potential Board Changes | MT |
| 06-26 | Beximco suspension lifted; M1 payment date extension | AN |
| Market Cap | 62.28B 505M 449M 420M 381M 719M 48.72B 724M 5.04B 1.96B 24.85B 1.9B 1.86B 79.9B | P/E 2026 * |
7.19x | P/E 2027 * | 6.28x |
|---|---|---|---|---|---|
| Enterprise Value | 62.28B 505M 449M 420M 381M 719M 48.72B 724M 5.04B 1.96B 24.85B 1.9B 1.86B 79.9B | EV / Sales 2026 * |
1.14x | EV / Sales 2027 * | 1.02x |
| Free-Float |
85.91% | Yield 2026 * |
4.31% | Yield 2027 * | 4.94% |
| 1 day | -2.24% | ||
| 1 week | -5.74% | ||
| Current month | -5.42% | ||
| 1 month | -8.88% | ||
| 3 months | -7.30% | ||
| 6 months | +22.24% | ||
| Current year | +36.73% |
| 1 week | 138.5 |  | 150.2 |
| 1 month | 138.5 | | 153.8 |
| Current year | 99.5 | | 158.5 |
| 1 year | 99.5 | | 158.5 |
| 3 years | 64.2 | | 158.5 |
| 5 years | 64.2 | | 253.8 |
| 10 years | 47.36 | | 255.4 |
| Manager | Title | Age | Since |
|---|---|---|---|
Iqbal Ahmed
CEO | Chief Executive Officer | - | 2024-03-03 |
| Director of Finance/CFO | 63 | 2002-12-31 | |
| Chief Tech/Sci/R&D Officer | - | - |
| Director | Title | Age | Since |
|---|---|---|---|
| Chairman | - | 2009-06-18 | |
| Director/Board Member | - | 2010-01-31 | |
Iqbal Ahmed
BRD | Director/Board Member | - | 1984-12-31 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -2.24% | -5.74% | +17.91% | -4.51% | 517M | |
| +1.26% | -2.29% | +36.97% | +104.79% | 1,019B | |
| +0.73% | -4.78% | +35.41% | +61.62% | 610B | |
| +0.35% | +1.29% | +15.86% | +79.90% | 470B | |
| +1.72% | -4.92% | +59.84% | +36.64% | 344B | |
| +0.26% | -1.58% | +21.97% | +41.79% | 336B | |
| +0.60% | -3.48% | +11.37% | +34.33% | 266B | |
| +1.65% | -4.27% | -5.47% | +9.69% | 241B | |
| -0.09% | -4.97% | +36.88% | +50.52% | 218B | |
| -0.28% | -4.66% | +26.99% | +92.98% | 179B | |
| Average | +0.39% | -3.81% | +25.77% | +50.77% | 368.33B | |
| Weighted average by Cap. | +0.85% | -3.51% | +29.67% | +67.24% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 54.78B 445M 395M 369M 335M 632M 42.85B 637M 4.44B 1.73B 21.86B 1.67B 1.63B 70.28B | 61.27B 497M 441M 413M 374M 707M 47.93B 712M 4.96B 1.93B 24.45B 1.87B 1.83B 78.6B |
| Net income | 8.66B 70.29M 62.4M 58.39M 52.93M 99.95M 6.78B 101M 701M 273M 3.46B 264M 258M 11.11B | 9.92B 80.49M 71.45M 66.87M 60.61M 114M 7.76B 115M 803M 312M 3.96B 302M 296M 12.73B |
| Net Debt | - | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26-10-05 | BDT 139.60 | -2.24% | 512,993 |
| 26-10-05 | BDT 142.80 | -1.18% | 280,589 |
| 26-10-04 | BDT 144.50 | -1.83% | 632,681 |
| 26-10-01 | BDT 147.20 | -0.27% | 391,420 |
| 26-09-30 | BDT 147.60 | +0.27% | 1,489,179 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Annual profits - Rate of surprise
- Stock Market
- Stocks
- BXPHARMA Stock
Select your edition
All financial news and data tailored to specific country editions
